MedTrace Logo

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

NCT02105792 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 820

Last updated 2018-06-21

No results posted yet for this study

Summary

This study will examine extreme responders to second- and third-line Type 2 diabetes therapy using a prospective approach, and patients with slow or fast diabetes progression using a retrospective approach.

Conditions

Interventions

DRUG

second- or third-line glucose-lowering diabetes treatment

Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.

Sponsors & Collaborators

  • University of Exeter

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • King's College Hospital NHS Trust

    collaborator OTHER

  • University of Glasgow

    collaborator OTHER

  • NHS Greater Glasgow and Clyde

    collaborator OTHER

  • Newcastle University

    collaborator OTHER

  • Newcastle-upon-Tyne Hospitals NHS Trust

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • Royal Devon and Exeter NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Andrew T Hattersley, FRCP, DM, BM · University of Exeter

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-05-31
Completion
2016-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02105792 on ClinicalTrials.gov